|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 4, July-August 2018
SEVERE TOXICITY TO CAPECITABINE FOR POSSIBLE ENZYMATIC DEFICIENCY
PRIETO CASTELLÓ MANUEL, HERNÁNDEZ LORENTE EVA, ESCOÍN PÉREZ CORINA, TABERNER BONASTRE TERESA
Dihydropyrimidine dehydrogenase (DPD) is the limiting enzyme involved in the degradation of 5-FU and, therefore, there is a close relationship between DPD levels and the effect of capecitabine. The deficiency of this enzyme can cause severe toxicity even leading to death. We describe a case of grade IV mucocutaneous
toxicity due to a possible DPD deficit, and analyzed the causality using the modified Karch-Lasagna algorithm.
Although the screening of the DPD deficit would allow to individualize the doses in these patients, these determinations are not implemented in the daily practice of most hospitals.
Capecitabine – Dihydropyrimidine Dehydrogenase – Toxicity